Sunday Short Courses
Additional fees apply. Visit https://www.slas2020.org/program/short-course-program/ for registration fees.
Cell-based in vitro assays are used throughout the drug discovery and development chain, allowing for high-throughput efficacy but also mechanistic-based toxicity testing. A big challenge, however, is the translation of in vitro assays towards the in vivo outcome. Physiological relevance is a key parameter to improve the predictive power of cell-based assays. The better we can reflect tissue architecture, composition and function the more predictive an in vitro assay will become. The 3D course covers advances in 3D cell culture technologies, assays and their use in drug discovery and development.
Who Should Attend
Industry and academic scientists with mid- to advanced-level experience in cell-based assays or cell biology wishing to get a concise overview about technologies, advantages, cost and application examples of 3D cell-based assays.
• Guidelines how to develop 3D cell-based assays.
• Guidelines how to use 3D models for phenotypic drug discovery
• State of the art overview about current methods in the rapidly evolving field of 3D cell-based assays.
• Solid starting point for participants interested in introducing 3D cell-based assays in their organization.
• Gaining expertise to use advanced cell culture models for drug discovery and drug development
• In-depth overview of 3D cell culture technologies and models: Comparison of the most important methods for 3D cell culture including hydrogel, scaffold, self-assembly, bioprinting and multi-organ devices; implementation strategies, automationand work flows; comparison of advantages, disadvantages and cost.
• How to adapt assays and readouts for 3D cell culture models: Using and optimizing existing biochemical assays; applying imaging technology for growth-curve measurements; histology and immune histochemistry; high-content analysis
• Case studies for the use of 3D models in drug discovery: 3D tumor models; co-culture systems; applications in screening of large libraries; target validation and3D-based phenotypic drug discovery
• Case studies for the use of 3D and multi-organ models in development: Toxicology-related models derived either from primary cell sources or stem cells and their use for safety testing such as liver toxicology andinflammation-mediated toxicology